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Aims: To assess the relationship between endothelial dysfunction, endothelin 1 (ET-1) plasma levels and sub-
clinical inﬂammation in primary open angle glaucoma (POAG) patients.
Main methods: We enrolled 40 POAG patients with progressive visual ﬁeld damage, although well controlled
intraocular pressure (IOP) and compared to age and sex matched healthxy subjects. Each patient underwent
an ophthalmological examination, a standard achromatic perimetry (SAP), blood sampling to assess ET-1 plas-
ma levels, an objective assessment of cellularity within the anterior chamber (FLARE) and measurement of ﬂow
mediated dilation (FMD) with high resolution 2-dimensional ultrasonographic imaging of the brachial artery.
Key ﬁndings: At baseline, POAG patients, compared to healthy controls, showed an increase of ET-1 plasma
levels: 2.83±0.28 pg/ml vs. 1.75±0.25 pg/ml (pb0.001), lower FMD values 4.46±1.28% vs. 13.18±2.80%
(pb0.001) and increased FLARE values 9.98±0.97 photons/ms vs. 5.87±0.64 photons/ms (pb0.001). A follow
up after 1 year revealed a further increase of ET-1 plasma levels (to 3.68±0.60; pb0.001) and decrease of FMD
(3.52±1.28; p>0.001).
Signiﬁcance: The increase of ET-1 in POAG patients is related to vascular dysfunction (r=0.942; p=0.001) and
vascular dysfunction is related to sub-clinical intraocular inﬂammation (r=0.968; p=0.001). Thus ET-1 and
vascular dysfunction related to sub-clinical inﬂammation may play a key role in determining a progressive vi-
sual ﬁeld damage in POAG patients who present a well-controlled IOP.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Glaucoma, a progressive optic neuropathy, is the second largest cause
of blindness worldwide (Congdon et al., 2003; Quigley, 2005). Elevated
intraocular pressure (IOP) is by far themostwidely recognised risk factor
that can be treated to slowdown the rate of progression of glaucomatous
damage (Coleman and Caprioli, 2009). Nevertheless, despite well-
controlled IOP, this neurodegenerative disease can still progress (Leske
et al., 2007; Mackenzie and Ciofﬁ, 2008). Over the last few years, there
has been mounting evidence in literature on the possible role played
by the ocular vascular system and associated vascular mediators in glau-
coma (Flammer andMozaffarich, 2007; Grieshaber and Flammer, 2005).
Endothelin-1 (ET-1) has been suggested to be a potential contributor
to the pathogenesis of glaucoma (Yorio et al., 2002). ET-1 is themost po-
tent vasoconstrictor known of small and large vessels (Masaki et al.,
1991). It is a peptide with 21 amino acid residues, mainly released by
the endothelial cells of the arterial, venous and lymphatic vessels
(Yanagisawa et al., 1988; Vane et al., 1989). Increased ET-1 plasma levels
have been described in normal tension glaucoma (NTG) (Sugiyama etliclinico S. Orsola-Malpighi, Via
: +39 51342821.
-NC-ND license.al., 1995; Cellini et al., 1997) but not in studies where primary open
angle glaucoma (POAG) patients had stable damage of the visual ﬁeld
(Tezel et al., 1997; Hollo et al., 1998). The fact that aqueous ET-1 levels
are increased in POAG (Tezel et al., 1997;Naske et al., 1997) underscores
the possible contribution of ET-1 to the pathogenesis of POAG. Further-
more, increased plasma levels of ET-1were found in POAG patients with
progressive disease (Emre et al., 2005).
Given that the endothelium is involved in the control of vascular
tone and blood ﬂow (Resch et al., 2009), vascular dysregulation can
be a consequence of endothelial dysfunction, so that we can evaluate
peripheral vascular endothelial function using a noninvasive and well-
established brachial artery ultrasound assessment of endothelium-
dependent ﬂowmediated dilation (FMD), an index of vasomotor func-
tion (Corretti et al., 2002; Deanﬁeld et al., 2007).
In this study we assessed ET-1 plasma levels, vascular endothelial
dysfunction and sub-clinical intraocular inﬂammation in healthy sub-
jects and POAG patients with progressive visual ﬁeld deterioration, at
baseline and after 1 year of follow up.
Materials and methods
We studied 40 POAG patients (22 males and 18 females; mean age
54.5±10.2 years) in good IOP control, but with progressive visual
Table 1
Demographic and clinical characteristics in the study groups at baseline.
POAG Controls P value
Number of patients (M:F) 40 (22:18) 40 (20:20) 0.750
Age (years) 54.5±10.2 52.9±7.1 0.834
Body mass index (Kg/m²) 25.77±2.73 23.85±3.47 0.103
Systolic blood pressure (mmHg) 125.13±15.03 123.00±15.22 0.702
Diastolic blood pressure (mmHg) 76.80±7.45 78.67±7.66 0.504
Total cholesterol (mg/dl) 194.42±29.21 188.73±24.41 0.567
HDL-cholesterol (mg/dl) 53.37±13.16 48.66±12.38 0.321
LDL-cholesterol (mg/dl) 116.22±26.81 115.70±24.85 0.956
Triglycerides (mg/dl) 107.85±62.77 103.54±47.75 0.834
Serum glucose (mg/dl) 92.30±7.97 93.29±9.20 0.754
BCVA (LogMAR) 0.89±0.2 1.0±0.1 0.257
C/D ratio 0.69±0.1 0.29±0.13 0.001
Corneal thickness (μm) 549.6±15.25 551.6±12.57 0.230
All data represent mean values±Sd.
POAG=primary open angle glaucoma; M=male; F=female; HDL=high density
lipoprotein; LDL=low density lipoprotein; ET-1=endothelin-1; BCVA=best cor-
rected visual acuity; IOP=intraocular pressure; C/D=cup and disc ratio.
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Orsola-Malpighi Hospital, and 40 healthy controls (20 males and 20
females; mean age 52.9±7.1 years), all recruited amongst visitors
to and staff of that service.
The study was conducted in compliance with the Declaration of
Helsinki and was approved by the institutional review board and in-
dependent ethical committee. The inclusion criteria for POAG patients
were: IOPb20 mmHg after treatment with carbonic anhydrase inhib-
itors eye drops, open anterior chamber angle at gonioscopy, cup/disc
ratio≥0.6 and an optic nerve-related visual ﬁeld loss mean defect
(MD) of >6 dB in the last three standard automated perimetry esti-
mations. Criteria for reliability of the visual ﬁeld tests were≤33%
false positive, ≤33% false negative and≤20% ﬁxation losses. The def-
inition of visual ﬁeld defect progression consisted of deepening of an
existing scotoma, expansion of an existing scotoma or a new scotoma
in a previously normal region of the visual ﬁeld in the last three tests.
Exclusion criteria were: age>65 years, smoking, autoimmune dis-
ease, consumption of systemic medications such as antihypertensive
drugs, cholesterol-lowering agents, aspirin or nitrates, and cardiovascu-
lar disease or known cardiovascular risk factors such as hypertension,
diabetes mellitus, dyslipidemia, in order to clear the study sample
from possible confounders affecting endothelial function. Furthermore,
we excluded patientswith a history of previous eye surgery. All patients
underwent an ophthalmologic examination including visual acuity and
IOP assessment, with Goldmann applanation tonometry, corneal thick-
ness evaluationwith a Tomey SP3000 pakimeter (Tomey Corp., Nagoya,
Japan) biomicroscopy of the anterior and posterior segment and auto-
matic measurement of the C/D area ratio of the optic nerve head with
Stratus OCT3 (Zeiss-Humphrey, Dublin, CA).
Standard achromatic perimetrywas also performedwith aHumphrey
Field Analyzer, using a 30-2 full threshold program (Carl Zeiss Meditec,
Inc., Dublin, CA, USA). All subjects gave informed written consent before
enrolment.
For each subject, before the beginning of the ultrasound measure-
ment of FMD, body mass index, blood sampling to assess lipid proﬁle,
fasting serum glucose and ET-1 plasma levels and an objective assess-
ment of cellularity within the anterior chamber (FLARE) were obtained
and after a follow up of 1 year, FMD, ET-1 plasma levels and FLAREwere
repeated.
For ET-1 measurements the plasma samples were drawn from the
antecubital vein and collected in a container with EDTA, cooled and
stored in ice. Subsequently, the samples were centrifuged at 4 °C and
frozen at −25 °C. After centrifugation the extraction was performed
using a Sep-column containing C-18 (Peninsula Laboratories, Belmont,
CA, USA). ET-1 concentration was determined using a commercial ra-
dioimmunoassay (RIA) kit (Peninsula Laboratories, Belmont, CA, USA).
For the RIA, samples and standards were incubated with rabbit anti-
ET-1 serum for 24 hours at 4 °C. A second 24 hours incubation was
made after the addition of an iodinated tracer [125 I]-ET-1. Free and
bound radioligands were separated with centrifugation and radioactiv-
ity in the precipitate was counted with an automatic gamma-counter.
The cellularity of the anterior chamber was evaluated with a laser
ﬂare-cell meter (FM 500 Kowa, Tokio, Japan). The ﬂare cell meter
consisted of an He-Ne laser beam system, a photomultiplier mounted
on a slit-lamp microscope and a computer. The maximum power of
the He-Ne laser was 50 μW and the diameter of the focused beam
20 μm as measured in the air. The laser scanned the aqueous humor
by means an optical scanner. The sampling window (0.3x0.5 mm)
installed in the microscope, was aligned with the laser beam in the
aqueous humor. The intensity of light passing through the sampling
window was measured by means of a photon- counting photomulti-
plier and analysed by a computer.
When the laser beam is projected through the sampling window
in the anterior chamber it hits the particles (protein and/or cells) in
suspension in the aqueous humor and is diffused by these with an in-
tensity proportional to their concentration. It is possible to count anddifferentiate the number of cells present in the aqueous humor from
the proteins as the light diffused by them is greater than that diffused
by the ﬁne protein particles (Sawa, 1990).
All subjects underwent measurement of FMD with high resolution
2-dimensional ultrasonographic imaging of the brachial artery by
means of a Philips ENVISOR echography machine (Philips Medical
Systems, Best, The Netherlands) and a 4–7 MHz linear probe. The
FMD technique has been described in detail elsewhere (Corretti et
al., 2002).
Best corrected visual acuity (BCVA) was converted into the loga-
rithmof theminimumangle of resolution units (LogMAR) for the statis-
tical analysis and all data were analysed using Student's t test for
unpaired data to compare POAG patients and controls and Student's t
test for paired data to compare POAG patients at baseline and after
1 year. In those cases in which the standard deviation of the two groups
under examination appeared to be signiﬁcantly different, t test with
Welch correction was used. Spearman's correlation test was employed
to evaluate correlations between ET-1, FMD, FLARE and MD visual
ﬁeld index.
All statistical analyses were performed using GraphPad InStat ver-
sion 3.05 for Windows (GraphPad Software, San Diego, California,
USA). A pb0.05 value was considered to be statistically signiﬁcant.Results
Table 1 summarizes the demographic and clinical characteristics
of the POAG patients and healthy subjects. Only the C/D ratio param-
eter is signiﬁcantly different between the two groups (pb0.001).
At baseline in POAG patients, compared to healthy controls, we
found an increase of ET-1 plasma levels (2.83±0.28 vs. 1.75±
0.25 pg/ml; pb0.001), lower FMD values (4.46±1.28 vs. 13.18±
2.80%; pb0.001), higher FLARE values (9.98±0.97 vs. 5.87±0.64 pho-
tons/ms ; pb0.001) and higher MD values: (9.61±3.47 vs. 2.66±
1.39 dB; p>0.001) (Table 2).
After 1 year follow-up, among POAG patients, we observed a new
increase of ET-1 plasma levels (3.68±0.60 vs. 2.83±0.28 pg/ml;
pb0.001), a further decrease of FMD values (3.52±1.28 vs. 4.46±
1.28%: pb0.039), unchanged FLARE values (9.93±0.85 vs. 9.98±
0.97 photons/ms; pb0.736) and higher MD values (12.15±3.49 vs.
9.61±3.47 dB; pb0.007) (Table 2).
The IOP in POAG group at baseline was not signiﬁcantly different
from that measured in the control group (17.42±1.30 mmHg vs.
17.44±1.76 mmHg; pb0.477) or from that assessed in the same
group 1 year later (17.47±0.86 mmHg vs. 17.42±1.30 mmHg;
pb0.433) (Table 2).
Table 2
Difference in vascular dysfunction, visual ﬁeld index, IOP and aqueos ﬂare data be-
tween POAG patients and healthy controls at baseline and among POAG patients
after 1 year.
Controls
(baseline)
POAG
(baseline)
P value POAG
(follow-up)
P value
ET-1 (pg/ml) 1.75±0.25 2.83±0.28 0.001 3.68±0.60 0.001
FMD % 13.18±2.80 4.46±1.28 0.001 3.52±1.28 0.039
FLARE
(photons/ms)
5.87±0.64 9.98±0.97 0.001 9.93±0.85 0.736
MD (dB) 2.66±1.39 9.61±3.47 0.001 12.15±3.49 0.007
IOP (mm/Hg) 17.44±1.76 17.42±1.30 0.477 17.47±0.86 0.433
The number of patients is 40.
ET-1=endothelin-1; FMD=ﬂow mediated dilation; MD=visual ﬁeld index “mean
defect”; IOP=intraocular pressure; FLARE=aqueous ﬂare.
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crease of ET-1 in POAG is related to vascular dysfunction (r=0.942;
p=0.001) and intraocular inﬂammation (r=0.968; p=0.001). Vas-
cular dysfunction is related to intraocular inﬂammation (r=0.953;
p=0.001) and to ET-1 plasma levels (r=0.942; p=0.001). Further-
more the progression of the visual ﬁeld damage is related to ET-1
plasma levels (r=0.746; p=0.002) and to vascular dysfunction
(r=0.690; p=0.001) but it is not related neither to IOP (r=-
0.199; p=0.401) nor to intraocular inﬂammation (r=-0129;
p=0.527). Finally the values of ET-1 (r=-0.046; p=0.845), FMD
(r=-344; p=0.137) and FLARE (r=0.072; p=0.762) are not age-
related.
Discussion
Glaucoma is a group of diseases featuring multiple risk factors that
may act with variable importance and severity. The IOP is by far the
most widely recognized risk factor and usually the only one that is
therapeutically targeted in the clinical setting (Weinreb and Khaw,
2004; Levin, 2005); nevertheless increasing interest has been focused
on a better understanding of the ocular hemodynamic in glaucoma
patients.
Our study highlighted that POAG patients showed increased ET-1
plasma levels (pb0.001), a systemic vascular endothelial dysfunction
detectable with a lowered FMD (pb0.001) and an increase of aqueous
ﬂare (pb0.001), compared to control group. One year after the origi-
nal baseline measurements, plasma ET-1 levels and MD measure-
ments progressed and FMD values decreased further in POAG
patients, despite the fact that IOP was controlled and FLARE did not
show any additional increase.
Furthermore we demonstrated that the increase of ET-1 in our pa-
tients was related to vascular dysfunction (r=0.942; p=0.001), that
vascular dysfunctionwas related to sub-clinical intraocular inﬂammationTable 3
Correlation between FMD, ET-1, FLARE, MD and IOP in POAG patients.
Spearman's rank correlation test FMD FLARE IOP MD
ET-1 r=0.942 r=0.968 r=0.118 r=0.746
p=0.001 p=0.001 p=0.619 p=0.002
FMD r=0.953 r=0.044 r=0.690
p=0.001 p=0.852 p=0.001
FLARE r=0.082 r=-0.129
p=0.728 p=0.527
IOP r=-0.199
p=0.401
The number of patients is 40.
ET-1=endothelin-1; FMD=ﬂow mediated dilation; MD=visual ﬁeld index “mean
defect”; IOP=intraocular pressure; FLARE=aqueous ﬂare.(r=0.953; p=0.001), and that increase in ET-1 levels was related to the
progression of both the visual ﬁeld damage (r=0.746; p=0.002) and
vascular dysfunction (r=0.690; p=0.001), as revealed by Spearman's
rank correlation test.
In past literature the importance of the vascular factor in the onset
and progression of glaucomatous optic neuropathy was emphasized
not only for NTG patients (Sugiyama et al., 1995; Cellini et al., 1997;
Butt et al., 1997), but also for POAG patients (Flammer, 1994;
Hayreh, 1997) and many recent studies have conﬁrmed the validity
of that hypothesis (Emre et al., 2005; Flammer et al., 2002; Pache et
al., 2002; Galassi et al., 2003; Zink et al., 2003; Fuchsjäger-Mayrl et
al., 2004).
The main mediators acting on ocular blood circulation are nitric
oxide (NO), synthesized by the endothelial isoform of nitric oxide
synthase enzyme and ET-1 that, interacting with ETA receptors on
vascular smooth muscle cells, causes a marked vasoconstriction
(Yanagisawa et al., 1988; Arai et al., 1990).
At the ocular level, ET-1 can reduce the ocular blood ﬂow in the ret-
ina, choroid and optic nerve head (Schmetterer et al., 1997; Polak et al.,
2001, 2003), causing a vasoconstriction in the posterior ciliary arteries,
but also, may exert direct receptor mediated effects on retinal ganglion
cells, where both ETA and ETB receptors are expressed, so it is possible
that increased ET-1 levels in glaucoma play a role in the astrocyte prolif-
eration that occurs in glaucomatous optic neuropathy (Zimmermann,
1997). Finally, there is evidence that the increased aqueous levels of
ET-1 in POAG reduce aqueous humor outﬂow by inducing contraction
of trabecular meshwork ﬁbers (Cellini et al., 2006).
Endothelium is a complex organ that regulates hemostasis, in-
ﬂammation, and vascular tone, which is highly dependent on both
the balance between NO and ET-1 (Moncada and Higgs, 1993;
Webb and Haynes, 1993) and the preserved function of the vascular
endothelial cells (Springer, 1995).
Moreover chronic endothelial dysfunction is characterized by an
altered turnover of the endothelial cells due to a reduced availability
of endothelial progenitor cells (Asahara et al., 1997; Hill et al., 2003;
Fadini et al., 2009), with a subsequent reduced biosynthesis and/or
bioavailability of NO and raised levels of superoxide anions and ET-1.
FMD is a standard, non invasive, repeatable and endothelium-
dependent technique that is used for an in vivo assessment of peripheral
vascular endothelial functionality. It is often used to determine cardio-
vascular disease risk factors in cardiovascular research (Anderson et
al., 2000), but more recently has also been adopted in ophthalmological
studies to investigate peripheral vascular endothelial functionality in
glaucoma patients (Su et al., 2008), in NTG (Su et al., 2006) and pseu-
doexfoliative syndrome (Atalar et al, 2006).
The presence of normal range ET-1 plasma levels in POAG patients
with stable visual ﬁeld (Cellini et al., 1997), together with altered oc-
ular hemodynamic on color Doppler imaging examination (Cellini et
al., 1996) suggests that vascular endothelial dysfunction is an event
that comes before the increase of plasmatic ET-1 levels.
Furthermore experimental studies on systemic hypertension
show that production of vasoconstrictor substances by cyclooxygen-
ase, including vasoconstrictor prostanoids and reactive oxygen spe-
cies, contributes to the pathogenesis of endothelial dysfunction in
this disease (Luscher and Vanhoutte, 1986; Yang et al., 2003).
So endothelial dysfunction, which might be at least partially
caused by a sub- clinical inﬂammatory status may play a key role in
determining a progressive visual ﬁeld damage in POAG patients
who present a well controlled IOP.
Conclusion
Our study highlights that POAG patients with progressive visual
ﬁeld deterioration, despite a good IOP control, show increased ET-1
plasma levels with a vascular dysfunction and increased FLARE
values.
702 M. Cellini et al. / Life Sciences 91 (2012) 699–702So in the causative mechanism of progression of visual ﬁeld dam-
age in POAG patients, who present a well controlled IOP, we speculate
that a sub-clinical inﬂammatory status may act as a trigger for the en-
dothelial dysfunction and for the alteration of ET-1 plasma levels.
Although these ﬁndings are suggestive, further studies are needed
to identify the exact causes of endothelial dysfunction and to ﬁnd the
most suitable therapeutic strategies.
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